Atreca, Inc. (BCEL)
After hours: 04:01PM EDT
Chart Events
Performance Outlook
| Previous Close | 5.63 |
| Open | 5.73 |
| Bid | 5.37 x 900 |
| Ask | 6.10 x 800 |
| Day's Range | 5.48 - 5.76 |
| 52 Week Range | 4.80 - 20.29 |
| Volume | 223,742 |
| Avg. Volume | 675,661 |
| Market Cap | 204.023M |
| Beta (5Y Monthly) | 0.03 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.36 |
| Earnings Date | Aug 10, 2021 - Aug 16, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.67 |
- GlobeNewswire
Atreca Announces Poster Presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
SAN CARLOS, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced two poster presentations at the SITC 2021 Annual Meeting, which is being held November 10-14, 2021 in Washington, D.C. Details are as follows: Title: First-in-Human Results with the Novel Tumor-Targeting An
- GlobeNewswire
Atreca to Present at Upcoming Virtual Investor Conferences
SAN CARLOS, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will present at the following upcoming virtual investor conferences: HC Wainwright 23rd Annual Global Investment ConferenceSeptember 13-15, 2021Presentation available beginning September 13 Baird G
- GlobeNewswire
Atreca Reports Second Quarter 2021 Financial Results and Recent Corporate Developments
SAN CARLOS, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the second quarter ended June 30, 2021, and provided an overview of recent developments. “We recently announced initial summary data from the dose escalation portion of the Phase 1b tr
